The Lancet Gastroenterology & Hepatology Hepatology

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →